Summary

Global Cholera Vaccines Market is valued at approximately USD 85.36 billion in 2023 and is poised to grow with a compelling compound annual growth rate (CAGR) of 10.00% over the forecast period 2024-2032. The fight against cholera—a potentially deadly bacterial infection caused by ingesting contaminated food or water—has become increasingly strategic and innovative in recent years. Vaccines targeting cholera have evolved from simple preventative tools into critical instruments for epidemic response, humanitarian aid missions, and long-term public health sustainability. These vaccines, particularly the oral formulations, offer scalable, low-barrier delivery to vulnerable populations, making them essential in safeguarding underserved regions across Africa, Asia, and parts of Latin America.
The market is witnessing vigorous tailwinds due to global collaborations between government agencies, vaccine manufacturers, and non-profit health organizations like Gavi and WHO. These partnerships are not only enhancing production capacity but also streamlining supply chain logistics for high-demand zones. Additionally, the rising frequency of cholera outbreaks driven by climate change, poor sanitation, and displacement crises has escalated demand for fast-acting, effective vaccines. Notably, products like Vaxchora have emerged as key solutions in traveler and military healthcare, while Dukoral is frequently utilized in endemic areas. However, production limitations, stringent storage conditions, and uneven access to healthcare remain critical constraints on widespread adoption.
Scientific advancements in recombinant DNA technology and whole-cell killed formulations are redefining the competitive landscape of cholera vaccines. Innovations in heat-stable vaccines, single-dose administration formats, and cost-effective production techniques are expanding market viability, especially in low-resource settings. Moreover, digital tracking systems and mobile vaccination campaigns are increasing immunization outreach and coverage in hard-to-reach populations. These evolutions are not only accelerating emergency response during outbreaks but are also supporting long-term preventive programs, contributing to the eventual goal of cholera elimination in some nations.
North America holds a commanding position in the global cholera vaccine landscape, primarily due to robust regulatory frameworks, government-funded vaccine programs, and the presence of high-profile pharmaceutical companies. Europe trails closely behind with its extensive research infrastructure and high vaccine uptake rates. Meanwhile, Asia Pacific is anticipated to register the fastest growth rate, propelled by heightened public awareness, increasing investments in immunization infrastructure, and ongoing cholera outbreaks in densely populated regions such as India, Bangladesh, and the Philippines. Africa and Latin America also represent important frontiers, where international health alliances are facilitating greater vaccine deployment and improving healthcare accessibility.
Major market player included in this report are:
• Emergent BioSolutions Inc.
• Valneva SE
• Celldex Therapeutics Inc.
• Sanofi S.A.
• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• Astellas Pharma Inc.
• Bharat Biotech International Ltd.
• Takeda Pharmaceutical Company Limited
• PaxVax Inc.
• GlaxoSmithKline plc
• EuBiologics Co., Ltd.
• Incepta Pharmaceuticals Ltd.
• Merck & Co., Inc.
• Bio-Manguinhos/Fiocruz
The detailed segments and sub-segment of the market are explained below:
By Type
• Whole cell V. Cholerae O1
• Recombinant With B-Subunit
By Product
• Vaxchora
• Dukoral
By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa
Years considered for the study are as follows:
• Historical Year – 2022
• Base Year – 2023
• Forecast Period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1. Global Cholera Vaccines Market Executive Summary
1.1. Global Cholera Vaccines Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Type
1.3.2. By Product
1.3.3. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Cholera Vaccines Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Cholera Vaccines Market Dynamics
3.1. Market Drivers
3.1.1. Escalating Frequency of Cholera Outbreaks
3.1.2. Strengthened Public–Private Vaccination Initiatives
3.1.3. Advances in Recombinant and Whole-Cell Formulations
3.2. Market Challenges
3.2.1. Cold-Chain and Storage Constraints
3.2.2. Production Capacity Limitations
3.2.3. Uneven Healthcare Access in Endemic Regions
3.3. Market Opportunities
3.3.1. Development of Heat-Stable and Single-Dose Vaccines
3.3.2. Expansion of Mobile Vaccination Campaigns
3.3.3. Digital Tracking and Supply-Chain Optimization
Chapter 4. Global Cholera Vaccines Market Industry Analysis
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s Model
4.1.7. Porter’s Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Cholera Vaccines Market Size & Forecasts by Type, 2022-2032
5.1. Segment Dashboard
5.2. Whole cell V. Cholerae O1 Revenue Trend Analysis, 2022 & 2032 (USD Million)
5.3. Recombinant With B-Subunit Revenue Trend Analysis, 2022 & 2032 (USD Million)
Chapter 6. Global Cholera Vaccines Market Size & Forecasts by Product, 2022-2032
6.1. Segment Dashboard
6.2. Vaxchora Revenue Trend Analysis, 2022 & 2032 (USD Million)
6.3. Dukoral Revenue Trend Analysis, 2022 & 2032 (USD Million)
Chapter 7. Global Cholera Vaccines Market Size & Forecasts by Distribution Channel, 2022-2032
7.1. Segment Dashboard
7.2. Hospital Pharmacy Revenue Trend Analysis, 2022 & 2032 (USD Million)
7.3. Retail Pharmacy Revenue Trend Analysis, 2022 & 2032 (USD Million)
Chapter 8. Global Cholera Vaccines Market Size & Forecasts by Region, 2022-2032
8.1. North America Market
8.1.1. U.S. Market
8.1.1.1. Type Breakdown & Forecasts, 2022-2032
8.1.1.2. Product & Channel Breakdown & Forecasts, 2022-2032
8.1.2. Canada Market
8.2. Europe Market
8.2.1. UK Market
8.2.2. Germany Market
8.2.3. France Market
8.2.4. Spain Market
8.2.5. Italy Market
8.2.6. Rest of Europe Market
8.3. Asia Pacific Market
8.3.1. China Market
8.3.2. India Market
8.3.3. Japan Market
8.3.4. Australia Market
8.3.5. South Korea Market
8.3.6. Rest of Asia Pacific Market
8.4. Latin America Market
8.4.1. Brazil Market
8.4.2. Mexico Market
8.4.3. Rest of Latin America Market
8.5. Middle East & Africa Market
8.5.1. Saudi Arabia Market
8.5.2. South Africa Market
8.5.3. Rest of Middle East & Africa Market
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. Emergent BioSolutions Inc.
9.1.2. Valneva SE
9.1.3. Celldex Therapeutics Inc.
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Emergent BioSolutions Inc.
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. Valneva SE
9.3.3. Celldex Therapeutics Inc.
9.3.4. Sanofi S.A.
9.3.5. Pfizer Inc.
9.3.6. Johnson & Johnson Services, Inc.
9.3.7. Astellas Pharma Inc.
9.3.8. Bharat Biotech International Ltd.
9.3.9. Takeda Pharmaceutical Company Limited
9.3.10. PaxVax Inc.
9.3.11. GlaxoSmithKline plc
9.3.12. EuBiologics Co., Ltd.
9.3.13. Incepta Pharmaceuticals Ltd.
9.3.14. Merck & Co., Inc.
9.3.15. Bio-Manguinhos/Fiocruz
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes